MA47793A - Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque - Google Patents
Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïqueInfo
- Publication number
- MA47793A MA47793A MA047793A MA47793A MA47793A MA 47793 A MA47793 A MA 47793A MA 047793 A MA047793 A MA 047793A MA 47793 A MA47793 A MA 47793A MA 47793 A MA47793 A MA 47793A
- Authority
- MA
- Morocco
- Prior art keywords
- methyl
- ylethynyl
- hydrazide
- quinoline
- benzoyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN201721005414 | 2017-03-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA47793A true MA47793A (fr) | 2020-01-22 |
Family
ID=63521897
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA047793A MA47793A (fr) | 2017-03-15 | 2018-03-15 | Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque |
Country Status (8)
Country | Link |
---|---|
US (2) | US11351123B2 (fr) |
EP (1) | EP3596050A4 (fr) |
JP (2) | JP7234129B2 (fr) |
CN (1) | CN110494422A (fr) |
AU (1) | AU2018235446B2 (fr) |
CA (1) | CA3056348A1 (fr) |
MA (1) | MA47793A (fr) |
WO (1) | WO2018167802A1 (fr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2013256227B2 (en) | 2012-05-02 | 2017-06-15 | Georgetown University | Treating neural disease with tyrosine kinase inhibitors |
BR112023001330A2 (pt) * | 2020-07-31 | 2023-02-14 | Sun Pharma Advanced Res Co Ltd | N'-(2-cloro-6-metilbenzoil)-4-metil-3-[2-(3-quinolil)etinil]-benzohidrazida para tratamento da doença de alzheimer |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5200939B2 (ja) * | 2005-12-23 | 2013-06-05 | アリアド・ファーマシューティカルズ・インコーポレイテッド | 二環式ヘテロアリール化合物 |
JP5273037B2 (ja) * | 2006-05-08 | 2013-08-28 | アリアド・ファーマシューティカルズ・インコーポレイテッド | アセチレン性ヘテロアリール化合物 |
EP2089003A1 (fr) | 2006-11-09 | 2009-08-19 | Abbott GmbH & Co. KG | Forme de dosage pharmaceutique pour l'administration orale d'un inhibiteur de la tyrosine kinase |
CN103502217B (zh) * | 2011-01-21 | 2015-11-25 | 太阳医药高级研究有限公司 | 包含酪氨酸激酶抑制剂的二芳基乙炔酰肼 |
US9456992B2 (en) | 2012-01-13 | 2016-10-04 | Xspray Microparticles Ab | Pharmaceutical composition comprising stable, amorphous, hybrid nanoparticles of at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix forming component |
US10022337B2 (en) * | 2013-11-15 | 2018-07-17 | Dsm Ip Assets B.V. | Formulation of sparingly soluble compounds by hot-melt extrusion |
EP2913048A1 (fr) | 2014-02-27 | 2015-09-02 | ratiopharm GmbH | Composition pharmaceutique comprenant de la trametinib |
PT107846B (pt) * | 2014-08-01 | 2019-03-22 | Hovione Farm S A | Produção de nano- partículas de dispersões sólidas amorfas por co-precipitação controlada |
TWI718102B (zh) | 2014-08-08 | 2021-02-11 | 日商中外製藥股份有限公司 | 4環性化合物的非晶質體 |
US20170360791A1 (en) * | 2014-12-04 | 2017-12-21 | Astex Pharmaceuticals, Inc. | Pharmaceutical compositions for increasing the bioavailability of poorly soluble drugs |
-
2018
- 2018-03-15 CN CN201880018595.XA patent/CN110494422A/zh active Pending
- 2018-03-15 MA MA047793A patent/MA47793A/fr unknown
- 2018-03-15 CA CA3056348A patent/CA3056348A1/fr active Pending
- 2018-03-15 JP JP2019550727A patent/JP7234129B2/ja active Active
- 2018-03-15 EP EP18767879.2A patent/EP3596050A4/fr active Pending
- 2018-03-15 US US16/494,543 patent/US11351123B2/en active Active
- 2018-03-15 AU AU2018235446A patent/AU2018235446B2/en active Active
- 2018-03-15 WO PCT/IN2018/050146 patent/WO2018167802A1/fr unknown
-
2021
- 2021-05-13 US US17/319,583 patent/US20210267906A1/en active Pending
-
2022
- 2022-12-16 JP JP2022201433A patent/JP7514292B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
WO2018167802A1 (fr) | 2018-09-20 |
WO2018167802A9 (fr) | 2019-02-07 |
RU2019132068A (ru) | 2021-04-15 |
US20210267906A1 (en) | 2021-09-02 |
JP2023027309A (ja) | 2023-03-01 |
AU2018235446A1 (en) | 2019-10-03 |
US11351123B2 (en) | 2022-06-07 |
CA3056348A1 (fr) | 2018-09-20 |
US20200085751A1 (en) | 2020-03-19 |
EP3596050A4 (fr) | 2021-01-13 |
JP2020510066A (ja) | 2020-04-02 |
AU2018235446B2 (en) | 2022-04-07 |
EP3596050A1 (fr) | 2020-01-22 |
JP7234129B2 (ja) | 2023-03-07 |
CN110494422A (zh) | 2019-11-22 |
RU2019132068A3 (fr) | 2021-06-22 |
JP7514292B2 (ja) | 2024-07-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2017011535A2 (es) | Composiciones de ácido obeticólico y métodos de uso | |
DK3606909T3 (da) | Natriumsalt af n-((1,2,3,5,6,7-hexahydro-s-indacen-4-yl)carbamoyl)-1-isopropyl-1h-pyrazol-3-sulfonamid | |
CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
MA49039A (fr) | Nouvelles molécules bispécifiques de liaison à l'antigène capables de se lier spécifiquement à cd40 et à fap | |
MA44725A (fr) | Formulations d'un inhibiteur de lsd1 | |
MA46954A (fr) | Méthodes de traitement d'états inflammatoires | |
ECSP16093323A (es) | N-(cianometil)-4-(2-(4-morfolinofenilamino)pirimidin-4-il)benzamida | |
MA49847A (fr) | Production enzymatique d'hexoses | |
MA46180A (fr) | Analogues de l'amyline | |
MA42488A (fr) | Composés, compositions et procédés pour augmenter l'activité du cftr | |
DK3386991T3 (da) | Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase | |
MA47494A (fr) | Nouvelles utilisations d'anticorps anti-sirpg | |
DE102016116153A8 (de) | Wirksame verfolgung von orten persönlicher vorrichtungen | |
IT201700081449A1 (it) | Procedimento di purificazione dell'acido ialuronico | |
MA42510A (fr) | Formes et compositions d'inhibiteurs biaryles de la tyrosine kinase de bruton | |
MA45917A (fr) | Sulfonamides en tant qu'agonistes de gpr40 et gpr120 | |
MA45987A (fr) | Agonistes des récepteurs 5-ht2c, compositions et méthodes d'utilisation | |
MA46422A (fr) | Oligonucléotides modifiés et méthodes d'utilisation | |
ECSP18018793A (es) | Compuestos útiles para inhibir ror-gamma-t | |
FR3056393B1 (fr) | Orthese d'extension de machoires | |
MA44862A (fr) | Formulations de fulvestrant et méthodes d'utilisation de celles-ci | |
CL2019002729A1 (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
MA47793A (fr) | Nouvelle dispersion amorphe d'hydrazide n'- (2-chloro-6-méthyl-benzoyl) d'acide 4-méthyl-3-quinoline-3-yléthynyle-benzoïque | |
DK3678644T3 (da) | Formuleringer af copanlisib | |
DK4132915T3 (da) | Substituerede isophtalsyrediamider |